3E: Biomaterials for the Lungs
Timeslot: Thursday, April 20, 2023 - 10:30am to 12:00pm
Room: Coral 3-4
About
The COVID-19 pandemic and its long-term consequences has put lung health in the spotlight. Advances in biomaterial design, drug delivery systems and microfabrication techniques offer new opportunities for probing disease mechanisms and novel therapies for lung diseases. These approaches can be used to develop treatments for acute conditions such as virus infections, to investigate mechanisms of chronic disease progression, for toxicology testing, and may even eliminate the need for animal experimentation in the future. This symposium will focus on the opportunities associated with using biomaterials to engineer the lung microenvironment, therapeutic delivery and potential impacts on clinical translation in pulmonary medicine.
10:30 AM 116. INVITED SPEAKER.
11:00 AM. 117. Local Matrix Stiffening as an Ex-Vivo Model of Early Pulmonary Fibrotic Remodeling. Donia Ahmed, Jingyi Xia, Rachel L. Zemans, M.D., Brendon M Baker, Ph.D., Claudia Loebel, M.D., Ph.D. University of Michigan.
11:15 AM. 118. Engineering a 3D Distal Lung Co-Culture Model of Human Pulmonary Fibrosis. Alicia E. Tanneberger, BS, MS, Chelsea M. Magin, PhD. University of Colorado Denver Anschutz.
11:30 AM. 119. Engineered Lung Microtissue to Model Macrophage-Regulated Pulmonary Fibrosis and Anti-Fibrosis Treatment. Ruogang Zhao, Ying Xu. State University of New York at Buffalo.
11:45 AM. 120. Lung-Mimetic Sealant: Lab-to-Market Translation via Biomedical Technology Accelerator. Meghan R. Pinezich, PhD, Mohammad Mir, Pamela L. Graney, PhD, Daniel Naveed Tavakol, Sarah R. Kaslow, MD, Panpan Chen, MD, Jiawen Chen, Maria R. Hudock, Olimpia Gavaudan, Brandon A.Guenthart, MD, Matthew Bacchetta, MD, John D. O'Neill, PhD, Jinho Kim, PhD, Gordana Vunjak-Novakovic, PhD. Columbia University, Stevens Institute of Technology, Stanford University, Vanderbilt University.